Immuron (IMRN) Cash & Equivalents (2016 - 2025)

Immuron has reported Cash & Equivalents for 10 years, with the latest figure at $28305.3 in Q3 2025.

• For the quarter ending Q3 2025, Cash & Equivalents fell 99.76% year-over-year to $28305.3; the trailing twelve-month figure through Sep 2025 stood at $28305.3 (down 99.76% YoY), and the FY2025 full-year result was $28305.3, down 99.76% from the prior year.
• Cash & Equivalents for Q3 2025 stood at $28305.3, down from $1.8 million in the prior quarter.
• The five-year high for Cash & Equivalents was $17.2 million in Q3 2023, with the low at $28305.3 in Q3 2025.
• Average Cash & Equivalents over 5 years is $7.9 million, with a median of $9.4 million recorded in 2023.
• Year-over-year, Cash & Equivalents soared 5087.14% in 2023 and tumbled 99.76% in 2025.
• Tracing IMRN's Cash & Equivalents over 5 years: stood at $2.4 million in 2021, then surged by 513.48% to $14.5 million in 2022, then slipped by 23.1% to $11.2 million in 2023, then plunged by 54.71% to $5.1 million in 2024, then sank by 99.44% to $28305.3 in 2025.
• The last three Cash & Equivalents figures came in at $28305.3 (Q3 2025), $1.8 million (Q2 2025), and $5.1 million (Q4 2024), per Business Quant data.

Peer Comparison